department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

FULVESTRANT · pharmadog

pharmadog
drugs
FULVESTRANT

drug

patient view →

FULVESTRANT

Marketedupdated 2mo ago

by Eagle Pharmaceuticals Inc

Approved

community read0 votes

all catalysts(4)

approval · 4

FULVESTRANT — FDA approval

FULVESTRANT — FDA approval

FULVESTRANT — FDA approval

FULVESTRANT — FDA approval

News(0)

no news has mentioned this drug yet

brand

FULVESTRANT

generic

FULVESTRANT

indication

Hormone Sensitive Breast Cancer

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 14, 2034

~7.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

May 17, 2034formulationUS 9271990
Feb 14, 2034formulationUS 10188663
Feb 14, 2034formulationUS 9833459

Data sources

openFDA · ClinicalTrials.gov

last refreshed 56m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 2

tagApproval8 co-mentions · 4 sources
tagSmall Molecule1 co-mentions · 1 sources

Trials studying FULVESTRANT

phase1[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Canceractive not recruitingn=28
phase1A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumorsrecruitingn=234
phase3A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapyactive not recruitingn=420
phase1A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumorsactive not recruitingn=103
phase3A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Canceractive not recruitingn=325
phase3Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.active not recruitingn=210
phase1BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumorscompletedn=33
phase1To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Canceractive not recruitingn=200

more trials →